In a recent study, Associate Professor Makoto Ikeya (Department of Clinical Application) and his team of researchers ...

In 502 patients with end-stage kidney disease (ESKD) receiving hemodialysis via AVG, time to a graft thrombosis event was not significantly different for those on 6 mg of MK-2060 (HR 0.83, 95% CI ...

This is the first-in-human phase 1/2a trial of Treg and bone marrow transplantation in HLA-mismatched living donor kidney transplant recipients.